Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVersarien Regulatory News (VRS)

  • This share is currently suspended. It was suspended at a price of 0.01
  • There is currently no data for VRS

Update on 2-DTech Ltd

4 Nov 2014 07:00

RNS Number : 0436W
Versarien PLC
04 November 2014
 

 

 

 

Press Release

4 November 2014

 

 

Versarien plc

("Versarien" or the "Group")

 

Update on 2-DTech Ltd

 

Versarien Plc (AIM:VRS), the advanced engineering materials group, is pleased to provide the following commercial update on 2-DTech Ltd ("2-DTech" or the "company"), the Group's graphene application and product development subsidiary which was acquired in May 2014.

 

Versarien also announces that 2-DTech will be hosting a site visit in Manchester for institutional investors, analysts and media on 19 November 2014. The site visit will enable the company to demonstrate the progress made since May in the commercialisation of graphene and will include a tour of the 2-DTech facility and presentations by leaders in this technology from 2-DTech and the University of Manchester.

 

In line with Versarien's strategy of supporting the road to product commercialisation through technology finance, 2-DTech has been awarded two separate grants from InnovateUK, formerly known as the Technology Strategy Board.

 

2-DTech will receive £80,000 for a collaborative project with Evodental, a leading dental implant company, to produce graphene-reinforced polymers for fixed dental prostheses.

 

• 2-DTech will receive £98,000 to explore the functionalisation of solid-state dye-sensitised solar cells which will be expedited in conjunction with Dyesol Ltd, the Australian solar clean tech company.

 

The InnovateUK grants supplement the existing £240,000 University of Manchester proof of concept grant for the commercialisation of a unique production process for which Versarien has now filed its first patent, jointly with the University of Ulster.

 

As a result of 2-DTech's progress and to strengthen the company's relationship with University of Manchester it has further strengthened the management team through two new senior appointments.

 

Dr. Aravind Vijayaraghaven, who is a lecturer in Nanomaterials at the University of Manchester, and is the public engagement coordinator for the National Graphene Institute, has joined 2-DTech as a Senior Consultant. The Board believes that Dr. Vijayaraghaven's reputation in the industry of nanomaterials and in the field of graphene will be of significant benefit to 2-DTech as it embarks on a number of planned collaboration projects.

 

2-DTech has also appointed Dr. Andrew Strudwick as a Research Scientist. Dr. Strudwick completed his PhD in the condensed matter physics department at the University of Leeds before working for BASF on commercialising graphene projects.

 

Neill Ricketts, Chief Executive Officer of Versarien, commented: "Since the acquisition in May, 2-DTech has made excellent progress with many of our key objectives being achieved well ahead of schedule whilst still keeping a strict control over costs. The two InnovateUK grants are testament to the hard work by 2-DTech and demonstrate our drive towards achieving early commercialisation of this very exciting discovery. We look forward to welcoming interested parties to the home of graphene where they will see how graphene is being developed and commercialised by 2-DTech through the combination of academic, scientific and commercial expertise."

 

For further information, please visit 2-DTech's new corporate website: http://2-dtech.com

 

- Ends -

 

For further information:

Versarien Plc

Neill Ricketts, Chief Executive Officer

Tel: +44 (0) 1594 888 622

Chris Leigh, Chief Financial Officer

www.versarien.com

 

Charles Stanley Securities

(Nominated Adviser and Broker)

Mark Taylor / Russell Cook

Tel: +44 (0) 20 7149 6000

 

Media Enquiries:

Abchurch Communications Limited

Henry Harrison-Topham / Jamie Hooper

Tel: +44 (0) 20 7398 7719

jamie.hooper@abchurch-group.com

www.abchurch-group.com

 

Notes to Editors

 

Versarien plc (AIM:VRS), is an advanced engineering materials group. Leveraging proprietary technology, the Group creates innovative engineering solutions for its clients in a diverse range of industries. Versarien has two wholly owned subsidiaries, Versarien Technologies Ltd and Total Carbide Ltd, and holds an 85% stake in 2-DTech Ltd.

 

Versarien Technologies Limited ("VTL")

VTL owns the exclusive rights to a patent-protected additive process for creating advanced micro-porous metals. Versarien primarily targets the thermal management industry exploiting the superb thermal properties exhibited by such materials. The company's lead product is VersarienCu, a micro-porous copper which on incorporation into liquid cooling systems, can improve efficiency by up to ten times. http://www.versarien.co.uk/

 

2-DTech Limited

On 1 May 2014, Versarien acquired 85% of the issued share capital of 2-DTech, a company closely aligned with The University of Manchester, the established home of graphene technology. 2-DTech specialises in the supply, characterisation and early stage development of graphene products. 2-DTech also works closely with industry and researchers to help turn scientific innovation into groundbreaking products. The acquisition will enable Versarien to apply its experience and expertise to commercialising graphene in the UK; demand for which is set to grow exponentially over the coming years. For further information about 2-DTech visit http://2-dtech.com/

 

Total Carbide Limited ("TC")

TC is one of the leading European manufacturers of sintered tungsten carbide, with a global customer base covering over forty different industries. It primarily manufactures arduous environment products for application in the oil and gas industry, along with multiple other industries. TC provides VTL with access to high volume manufacturing assets that have significantly expanded production of VersarienCu. http://www.totalcarbide.com/

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCLLFSDLALVIIS
Date   Source Headline
12th Dec 20249:59 amRNSHolding(s) in Company
11th Dec 20241:21 pmRNSHolding(s) in Company
4th Dec 20247:00 amRNS-RInvestor Presentation
27th Nov 20244:45 pmRNSHolding(s) in Company
26th Nov 20243:42 pmRNSHolding(s) in Company
21st Nov 202411:12 amRNSUpdate on Legal Claims
4th Nov 202412:07 pmRNSHolding(s) in Company
1st Nov 20247:00 amRNSTotal Voting Rights
31st Oct 202410:36 amRNSUpdate on Sale of Korean Assets
31st Oct 202410:14 amRNSHolding(s) in Company
18th Oct 202410:41 amRNSHolding(s) in Company
16th Oct 20247:00 amRNSPlacing to raise £450,000
4th Oct 20247:00 amRNSCorporate Update
30th Sep 20247:00 amRNSDisposal of AAC Cyroma Limited
14th Aug 20247:00 amRNS3D Construction Printing Contract
5th Aug 20241:16 pmRNSHolding(s) in Company
2nd Aug 202410:48 amRNSUpdate on Sale of Korean Assets
31st Jul 20242:30 pmRNSTotal Voting Rights
29th Jul 20241:47 pmRNSHolding(s) in Company
24th Jul 20247:00 amRNSPlacing to raise £550,000
18th Jul 20247:00 amRNSUpdate on Legal Claims
17th Jul 20247:00 amRNSConversion of Gnanomat Loan
6th Jun 20247:00 amRNSInterim Results for six months ended 31 March 2024
30th Apr 202411:59 amRNSResult of AGM
28th Mar 20247:00 amRNSAudited Results for year ended 30 September 2023
28th Mar 20247:00 amRNSTotal Voting Rights
20th Mar 20248:33 amRNSPlacing to raise £615,000
14th Mar 20247:00 amRNSSouth American Graphinks Agreements
11th Mar 20247:00 amRNSSale of Korean Assets and Licencing of IP
16th Feb 20242:22 pmRNSNotification of final results
7th Feb 20247:00 amRNSReceipt of Legal Claims
31st Jan 20247:00 amRNSTotal Voting Rights
23rd Jan 20244:53 pmRNSHolding(s) in Company
23rd Jan 20241:24 pmRNSHolding(s) in Company
19th Jan 20247:00 amRNSPlacing to raise £400,000
10th Jan 202411:29 amRNSResult of General Meeting
20th Dec 20237:00 amRNSCompany Update and Notice of General Meeting
30th Nov 20237:00 amRNSTotal Voting Rights
8th Nov 20237:00 amRNSPlacing to raise £454,822
30th Oct 202311:52 amRNSResult of General Meeting
30th Oct 20237:00 amRNSGeneral Meeting Statement
12th Oct 20237:00 amRNSNotice of General Meeting
2nd Oct 20237:00 amRNSCorporate Update
13th Sep 20237:00 amRNSTurnaround Strategy - Gnanomat Grant Award
31st Jul 20237:00 amRNSTotal Voting Rights
18th Jul 20234:31 pmRNSDirectorate Changes
14th Jul 20237:00 amRNSPlacing to raise £650,000
4th Jul 202310:54 amRNSResult of General Meeting
4th Jul 20237:00 amRNSGeneral Meeting Statement
15th Jun 20237:00 amRNSNotice of General Meeting

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.